A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)

Conditions: Advanced or Metastatic NRAS-mutant Melanoma Interventions: Drug: Naporafenib; Drug: Dacarbazine; Drug: Temozolomide; Drug: Trametinib Sponsors: Erasca, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials